Medrol

Methylprednisolone, the active ingredient in Medrol, is a corticosteroid presented as an oral tablet for systemic use. It is employed to reduce inflammation and modulate immune responses in a range of allergic, dermatologic, rheumatic, respiratory and autoimmune conditions, typically in adult and pediatric patients under medical supervision.

GNH USA supplies Medrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylprednisolone acts as a systemic anti‑inflammatory and immunosuppressive agent across several disease families.

- Allergic disorders: alleviates symptoms of severe allergic rhinitis, urticaria and angioedema. - Dermatologic conditions: reduces inflammation in eczema, psoriasis and severe cutaneous reactions. - Rheumatic diseases: controls joint inflammation and pain in rheumatoid arthritis and systemic lupus. - Respiratory diseases: improves airflow and reduces exacerbations in asthma and COPD. - Autoimmune and inflammatory disorders: suppresses immune activity in conditions such as inflammatory bowel disease and multiple sclerosis.

Methylprednisolone may cause a range of adverse reactions, varying with dose and duration.

Common Side Effects: - Increased appetite and weight gain. - Mood changes, including anxiety or insomnia. - Elevated blood glucose levels. - Gastrointestinal discomfort or ulceration. - Fluid retention leading to peripheral edema. - Mild skin thinning or bruising.

Serious or Rare Side Effects: - Severe infections due to immunosuppression. - Osteoporosis or pathological fractures. - Adrenal insufficiency on abrupt discontinuation. - Vision problems such as cataracts or glaucoma. - Psychiatric disturbances like psychosis. - Allergic reactions including rash or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Monitor blood glucose: check fasting glucose or HbA1c in diabetic or at‑risk patients. - Assess bone health: consider calcium, vitamin D supplementation and periodic bone density testing. - Screen for infections: evaluate for active or latent infections, especially tuberculosis. - Review psychiatric history: observe for mood swings, depression or psychotic symptoms. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Methylprednisolone can alter the pharmacokinetics or pharmacodynamics of several co‑administered agents.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase systemic exposure. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Anticoagulants (warfarin): enhanced anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal ulceration. - Diuretics: may exacerbate hypokalemia. - Antidiabetic drugs: possible need for dose adjustment due to hyperglycaemia.